Apellis Pharmaceuticals (APLS) Research & Development (2020 - 2025)
Historic Research & Development for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $68.2 million.
- Apellis Pharmaceuticals' Research & Development fell 2301.37% to $68.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.0 million, marking a year-over-year decrease of 702.78%. This contributed to the annual value of $327.6 million for FY2024, which is 756.72% down from last year.
- Apellis Pharmaceuticals' Research & Development amounted to $68.2 million in Q3 2025, which was down 2301.37% from $67.0 million recorded in Q2 2025.
- In the past 5 years, Apellis Pharmaceuticals' Research & Development registered a high of $110.0 million during Q1 2023, and its lowest value of $67.0 million during Q2 2025.
- In the last 5 years, Apellis Pharmaceuticals' Research & Development had a median value of $86.4 million in 2025 and averaged $86.1 million.
- Per our database at Business Quant, Apellis Pharmaceuticals' Research & Development surged by 5531.52% in 2021 and then plummeted by 3031.59% in 2023.
- Quarter analysis of 5 years shows Apellis Pharmaceuticals' Research & Development stood at $78.2 million in 2021, then increased by 27.17% to $99.4 million in 2022, then crashed by 30.32% to $69.3 million in 2023, then rose by 10.21% to $76.4 million in 2024, then decreased by 10.7% to $68.2 million in 2025.
- Its Research & Development stands at $68.2 million for Q3 2025, versus $67.0 million for Q2 2025 and $86.4 million for Q1 2025.